|
|
Upfront Briefing
The FDA changed its mind, and uniQure holders changed tax brackets — QURE ripped ~80% after the agency decided the AMT-130 Huntington's data it waved off in March is suddenly good enough to file. Amazing what a leadership reshuffle does. Biogen kept shopping too: an up-to-$1B, milestone-stuffed grab for RayThera, its second immunology bolt-on of the year and more proof it's done waiting on its own labs. The IPO window isn't just open, it's flexing — Kardigan priced an upsized $400M raise (2026's fourth to clear that bar) and lists on Nasdaq today, while Legend's $226M follow-on reminded everyone that "capital access" still rhymes with "dilution." All of it on the day Kevin Warsh's Fed told markets to behave. Biotech didn't.
Tape Action
| Instrument |
Last close |
1D % |
YTD % |
| S&P 500 |
7,420.1 |
(1.2%) |
8.2% |
| Nasdaq 100 |
29,670.9 |
(1.0%) |
17.7% |
| Russell 2000 |
2,918.0 |
(0.7%) |
16.3% |
| Healthcare (XLV) |
150.7 |
(1.5%) |
(3.1%) |
| Biotech (XBI) |
139.4 |
3.0% |
14.7% |
| Nasdaq Biotech (NBI) |
6,018.8 |
1.1% |
5.5% |
| Clinical Trials (BBC) |
44.8 |
4.2% |
19.1% |
|
- Biotech bucked the tape: XBI +3.0% and BBC +4.2% as Biogen's up-to-$1B RayThera immunology buyout and Kardigan's upsized $400M IPO pricing put a bid under drug-development names even as the broad market sold off.
- The broad drop was a Fed story — Kevin Warsh's first FOMC meeting held rates but guided hawkish, with the market now pricing a possible late-2026 hike; Treasury yields jumped, the S&P 500 fell 1.2% and the tech-heavy Nasdaq slid over 1%.
- Market data: U.S. cash close Wednesday, 17 June 2026.
The Big 3
|
1
|
Biogen to acquire RayThera in up to $1B deal
|
- RayThera’s lead anti-inflammatory program, poised to enter Phase 1, anchors Biogen’s up to $1B immunology buyout, with most of the value pushed into milestones.
-
Why it matters:
Second immunology bolt-on of the year for Biogen, after the ~$5.6B Apellis deal in March — a clear tell it's buying its way out of a generics-pressured neurology base rather than waiting on the labs. The structure does the work: a modest upfront with most of the $1B tied to clinical and regulatory milestones, so the balance-sheet hit is small and the risk sits with RayThera's holders. The catch is maturity — the lead anti-inflammatory asset only enters Phase 1 in Q3, so this is option value, not a near-term revenue line. BIIB slipped about 0.4% after hours; the Street isn't paying up for preclinical immunology yet.
- Source: Endpoints
- More: PR
|
|
2
|
Kardigan raises $400M in IPO
|
-
Kardigan (KARD) priced an upsized $400M IPO at $16 — top of the marketed range — to fund three clinical-stage cardio programs led by danicamtiv; shares debut on Nasdaq today.
-
Why it matters:
Priced at $16, top of range and upsized — the fourth biotech this year to clear $400M at IPO, the most since 2021 and the cleanest sign the new-issue window is genuinely open, not just ajar. Kardigan carries pedigree: built by ex-MyoKardia hands (the team BMS bought for $13B), with lead asset danicamtiv — licensed back from BMS — in Phase 2b/3 for genetic dilated cardiomyopathy, a disease with no approved therapy. The raise funds danicamtiv plus two more cardio programs without near-term partnering pressure. Watch how KARD trades its first session into a hawkish-Fed tape: a strong debut validates the larger-raise cohort; a soft one cools it.
-
Source:
Endpoints
-
More:
BioPharma Dive
|
|
3
|
FDA U-turn clears uniQure's AMT-130 to file; QURE +80%
|
-
The FDA reversed its March stance and told uniQure a three-year Phase 1/2 analysis can serve as the primary basis for an accelerated-approval filing for AMT-130 in Huntington's; the company plans to file in Q3, and QURE spiked about 80% to $48.51.
-
Why it matters:
In March the FDA said the three-year dataset wasn't enough; Wednesday it agreed that same analysis can anchor a filing for AMT-130 — the only gene therapy in reach for Huntington's, a disease with nothing disease-modifying on the market. QURE ripped ~80% to $48.51, and Regenxbio and Rezolute caught a sympathy bid as the Street read a softer, post-Makary/Prasad FDA on rare-disease evidence. The overhang: there's still no agreement on the confirmatory study — concurrent standard-of-care control vs. the sham the agency first wanted — and accelerated approval lives or dies on that design. This trades as much on FDA tea leaves as on uniQure.
-
Source:
Fierce Biotech
-
More:
uniQure;
BioCentury
|
Everything Else that broke
- F2G and Shionogi posted positive Phase 3 OASIS topline data for oral olorofim in invasive aspergillosis. — Endpoints
- FDA warned 25 telehealth firms over false and misleading compounded GLP-1 marketing claims. — Endpoints
- FDA accepted Roche’s sBLA for subcutaneous Lunsumio VELO plus Polivy in relapsed or refractory LBCL. — PR
- Nicox said China feedback supports an NDA filing for ophthalmology candidate NCX 470. — PR
- D&D Pharmatech reported AI-powered Phase 2 biopsy analysis showing liver fibrosis improvement with zabopegdutide in MASH. — PR
- BioCentury detailed a memo on Høeg’s reported role in blocking Tzield approval. — BioCentury
- Endpoints reported FDA is reconsidering some rejected drugs in the post-Makary era. — Endpoints
- A Senate draft would widen DoD sanction reach and research-security scrutiny on Chinese companies. — BioCentury
- Oncoinvent hit 50% enrollment in its Phase 2 ovarian cancer study of Radspherin. — PR
- Certara named a new CFO and reaffirmed 2026 guidance. — PR
- WuXi Biologics’ Suzhou testing site won a fourth EMA GMP certification, supporting 19 EU commercial products. — PR
Deal Flow
|
BioBucks 2026 Deal Trackers • Updated weekly ⬇️
|
M&A / BD&L
-
Biogen agreed to buy RayThera in an up to $1B, milestone-heavy immunology deal (see The Big 3). — Endpoints
-
Jazz struck a T-cell-engager antibody discovery pact with AbCellera (ABCL) — $56M upfront, up to $792M per program in option fees and milestones — targeting GI and other solid tumors, weeks after its Zepzelca Phase 3 missed on overall survival. — Fierce Biotech
VC / Private Financings
-
Vedana Therapeutics launched from stealth with a $46M Series A co-led by Westlake BioPartners and Canaan Partners (with Dawn Biopharma and Alexandria Venture Investments), backing subcutaneous anti-PACAP and PACAP/CGRP-bispecific antibodies for migraine prevention; both preclinical, first-in-human expected 2027. — Fierce Biotech
IPOs / Follow-Ons
- Kardigan raised $400M in its IPO to fund three clinical-stage cardio drugs (see The Big 3). — Endpoints
- Legend Biotech priced a $226M ADS follow-on at $29.35, with an option for 1.155M more ADSs. — PR
Academic Corner - Prehospital whole-blood transfusion was not superior to standard component transfusion in traumatic hemorrhage. — NEJM
- Endovascular therapy improved post-thrombotic syndrome severity and quality of life at 6 months, but raised bleeding risk. — NEJM
- Nature Medicine flagged CAR T’s deep responses in precancers alongside severe toxicity and patient-selection risk. — Nature Medicine
|
|
Markets go dark tomorrow for Juneteenth, so that 80% gene-therapy moonshot has to carry you through a three-day weekend. Try not to refresh the brokerage app.— BioBucks Team
|
|
|
